PMID- 16086558 OWN - NLM STAT- MEDLINE DCOM- 20051128 LR - 20060227 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 150 IP - 1 DP - 2005 Jul TI - Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. PG - 115 AB - BACKGROUND: This study was undertaken to evaluate the hypothesis that treatment with granulocyte colony-stimulating factor (G-CSF) to mobilize bone marrow cells (BMCs) is feasible and safe and promotes neovascularization and myocardial function in patients with acute myocardial infarction. METHODS: Fourteen patients in the treatment group and 9 patients in the control group were enrolled in this prospective, nonrandomized, open-label study. Forty-eight hours after successful recanalization and stent implantation, the patients of the treatment group received 10 microg/kg body weight per day G-CSF subcutaneously for mean treatment duration of 7.0 +/- 1.0 days. Nine patients fulfilled the entry criteria but refused participation and served therefore as control group. In both groups, regional wall motion and perfusion was evaluated with electrocardiogram-gated sestamibi single-photon emission computed tomography imaging and ejection fraction with radionuclidventriculography before discharge and after 3 months. RESULTS: No severe side effects of G-CSF treatment were observed. There was a significant improvement of the regional wall motion and perfusion within the treatment group (P < .0001) and between the treatment and control group (P < .05 and P < .01, respectively). Ejection fraction in the treatment group increased from 0.40 +/- 0.11 to 0.48 +/- 0.13 (P < .01), whereas in the control group, ejection fraction increased from 0.40 +/- 0.13 to 0.43 +/- 0.13 (P = .049). A control angiography of the treatment group after 12.4 +/- 6.6 months showed an in-stent restenosis in 1 patient. CONCLUSION: In patients with acute myocardial infarction, treatment with G-CSF to mobilize BMCs is feasible and safe and seems to be effective under clinical conditions. The therapeutic effect might be attributed to BMC-associated promotion of myocardial regeneration and neovascularization. FAU - Kuethe, Friedhelm AU - Kuethe F AD - Klinik fuer Innere Medizin I, Friedrich-Schiller-Universitaet Jena, Jena, Germany. friedhelm.kuethe@med.uni-jena.de FAU - Figulla, Hans R AU - Figulla HR FAU - Herzau, Michael AU - Herzau M FAU - Voth, Matthias AU - Voth M FAU - Fritzenwanger, Michael AU - Fritzenwanger M FAU - Opfermann, Thomas AU - Opfermann T FAU - Pachmann, Katharina AU - Pachmann K FAU - Krack, Andreas AU - Krack A FAU - Sayer, Herbert G AU - Sayer HG FAU - Gottschild, Dietmar AU - Gottschild D FAU - Werner, Gerald S AU - Werner GS LA - eng PT - Clinical Trial, Phase I PT - Journal Article PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Feasibility Studies MH - Female MH - Granulocyte Colony-Stimulating Factor/*therapeutic use MH - *Hematopoietic Stem Cell Mobilization MH - Humans MH - Male MH - Middle Aged MH - Myocardial Infarction/*therapy MH - Prospective Studies EDAT- 2005/08/10 09:00 MHDA- 2005/12/13 09:00 CRDT- 2005/08/10 09:00 PHST- 2005/01/21 00:00 [received] PHST- 2005/04/28 00:00 [accepted] PHST- 2005/08/10 09:00 [pubmed] PHST- 2005/12/13 09:00 [medline] PHST- 2005/08/10 09:00 [entrez] AID - S0002-8703(05)00461-8 [pii] AID - 10.1016/j.ahj.2005.04.030 [doi] PST - ppublish SO - Am Heart J. 2005 Jul;150(1):115. doi: 10.1016/j.ahj.2005.04.030.